Uncoupling of the mitochondrial respiration with FCCP after treatment with metformin and everolimus for 48 h. Using the seahorse XF analyzer, the basal OCR and maximal OCR after uncoupling of mitochondrial respiration with FCCP of MCF-7 (A) and MDA-MB-231 cells (B) in response to 48 h of metformin or everolimus treatment was determined. Basal OCR in untreated cells was set at 100% as a reference to which all other mitochondrial respiration values of the same glucose concentration group were correlated. Data are presented as mean ± SD of three different experiments. (PDF 69 kb
AMPK inhibition blocked metformin-mediated suppression. MSTO-211H cells were treated with metformin ...
Background: Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regul...
Figure S2. A. Fold changes of cell number was measured and plotted for shCon and shTPD54 stable cell...
Glucose concentration of cell culture medium during 4 days of metformin treatment. MCF-7 and MDA-MB-...
Figure S4. A. qRT-PCR results for mRNA levels of actin, AMPK, PDH E2, PDH E3bp and PDH E1α from MCF7...
Figure S3. A. Western blot detected PDH complex using the same samples presented in Fig. 1g. B. ECAR...
Figure S3 Expression of 8-hydroxydeoxyguanosine (8-OHdG) in breast tumours. Twenty days after the in...
Everolimus targets the phosphorylation of the PI3K/mTOR/Akt pathway at 48 and 72Â h. MCF-7, MCF-7:5C...
Figure S3. Aspirin and metformin synergize with fluvastatin to sensitize MCF10.AT1-R and MCF10.DCIS ...
Figure S5 Cell viability of treated MCF-7 cells was evaluated by LDH release assay on days (d) 1, 3,...
Figure S4 Expressed differences in mitochondrial dynamics and biogenesis between the human breast ep...
Measurement of Everolimus cytotoxicity on BC cell lines. Table S1. Primer sequences used for Real-Ti...
Figure S1. A. MTS assay was performed and plotted for the cell proliferation of shcon and shTPD54 ce...
OCR and ECAR measurement explanation. (A) i. Normally functioning cellular respiration utilizes elec...
Figure S2 Cell viability of the MCF-10A human breast epithelial cell line after 3âdays of treatmen...
AMPK inhibition blocked metformin-mediated suppression. MSTO-211H cells were treated with metformin ...
Background: Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regul...
Figure S2. A. Fold changes of cell number was measured and plotted for shCon and shTPD54 stable cell...
Glucose concentration of cell culture medium during 4 days of metformin treatment. MCF-7 and MDA-MB-...
Figure S4. A. qRT-PCR results for mRNA levels of actin, AMPK, PDH E2, PDH E3bp and PDH E1α from MCF7...
Figure S3. A. Western blot detected PDH complex using the same samples presented in Fig. 1g. B. ECAR...
Figure S3 Expression of 8-hydroxydeoxyguanosine (8-OHdG) in breast tumours. Twenty days after the in...
Everolimus targets the phosphorylation of the PI3K/mTOR/Akt pathway at 48 and 72Â h. MCF-7, MCF-7:5C...
Figure S3. Aspirin and metformin synergize with fluvastatin to sensitize MCF10.AT1-R and MCF10.DCIS ...
Figure S5 Cell viability of treated MCF-7 cells was evaluated by LDH release assay on days (d) 1, 3,...
Figure S4 Expressed differences in mitochondrial dynamics and biogenesis between the human breast ep...
Measurement of Everolimus cytotoxicity on BC cell lines. Table S1. Primer sequences used for Real-Ti...
Figure S1. A. MTS assay was performed and plotted for the cell proliferation of shcon and shTPD54 ce...
OCR and ECAR measurement explanation. (A) i. Normally functioning cellular respiration utilizes elec...
Figure S2 Cell viability of the MCF-10A human breast epithelial cell line after 3âdays of treatmen...
AMPK inhibition blocked metformin-mediated suppression. MSTO-211H cells were treated with metformin ...
Background: Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regul...
Figure S2. A. Fold changes of cell number was measured and plotted for shCon and shTPD54 stable cell...